By comparing treatment efficacy and cost, the authors evaluate the use of cisplatin and carboplatin for stage III or IV ovarian cancer. Differences in toxicity-related care, including hospitalizations, are investigated to ascertain the advisability of substituting one drug for another.
|Original language||English (US)|
|Journal||P and T|
|Publication status||Published - 1994|
ASJC Scopus subject areas